Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
Removing Endogenous TCR Chains for Enhanced TCR-Based Immunotherapies
USPTO published patent application US20260097079A1 by Khosravi Maharlooei et al. disclosing methods for treating diseases using adoptive cell therapy with modified lymphocytes having inactivated endogenous TCRα and TCRβ chains. The application covers compositions and methods for enhanced TCR-based immunotherapies.
Cell Behavior Control Methods Without Genetic Modification
USPTO published patent application US20260097078A1 by inventors Victor TETS and Georgy TETS covering products and methods for managing cell behavior, cell memory, and erasure of cell memory without genetic modification. The application relates to therapeutic, diagnostic, agricultural, and biomanufacturing applications. The invention distinguishes itself from prior art by enabling control of cellular properties without mutagens, gene introduction, or environmental condition changes.
Erythroid Lineages from Pluripotent Cells
USPTO published patent application US20260097074A1 by Dhvanit Shah disclosing methods for generating hematopoietic lineages including erythroid progenitor cells, progenitor erythroblasts, and erythroid cells from human induced pluripotent stem cells (iPSCs) for cell therapy applications. The application covers efficient ex vivo processes for developing these lineages and isolated cell compositions produced by the methods.
Modified Gamma Delta T Cells for Cancer Therapy
USPTO published patent application US20260097077A1 for a method of treating cancer using gamma delta T cells modified with XBP1 gene or protein inhibitors. The modified T cells demonstrate enhanced antitumor activity in tumor microenvironments with endoplasmic reticulum stress. Inventors are Minkyung Song, Hocheol Shin, and Ji Yun Park, with application filed September 4, 2025.
Method to Change Tumor Associated Macrophage Polarization Using Magnetosomes and Radiation
USPTO published patent application US20260097075A1 by Université Paris Cité for a method to change tumor-associated macrophage polarization by exposing macrophages to magnetosomes and radiation. The invention aims to shift macrophages from M0 or Mi polarization to Mj polarization for potential cancer immunotherapy applications.
Cbfβ-Expressing Vascular Smooth Muscle Cells for Age-Related Disease Treatment
The USPTO published patent application US20260097084A1 by Kyungpook National University Industry-Academic Cooperation Foundation covering a pharmaceutical composition containing Cbfβ-expressing vascular smooth muscle cells or culture fluid for preventing or treating age-related diseases. The invention demonstrates that Cbfβ expression in vascular smooth muscle cells inhibits osteoclast differentiation and prevents vascular calcification, offering potential therapeutic applications for conditions such as osteoporosis and age-related vascular disorders.
Pharmaceutical Composition Containing Neonatal Pig-Derived Mesenchymal Stem Cells for Treating Non-Porcine Animals
USPTO published patent application US20260097081A1 by Fukuoka University for a pharmaceutical composition containing neonatal pig-derived mesenchymal stem cells. The cells produce at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A, and VEGF-C for therapeutic use in treating cardiovascular conditions, wounds, and decubitus in non-porcine animals. The application was filed on October 10, 2025.
Heterotrophic Skin Bacteria Composition for Treating UV Damage and PLE
The USPTO published patent application US20260097086A1 by inventor Catherine O'Neill for a composition comprising heterotrophic skin bacteria or bacterial extract for modulating cytokine expression in skin cells. The composition is intended for preventing and treating skin damage caused by UV light and for treating polymorphous light eruption (PLE).
Engineered Immune Cells CAR-T CAR-NK BCMA TACI Cancer Therapy Patent Application
USPTO published patent application US20260097076A1 for engineered immune cells (T cells and NK cells) expressing chimeric antigen receptors targeting BCMA and/or TACI antigens for cancer therapy. The application discloses armored CAR-T and CAR-NK cells with enhanced features for tumor treatment. Filed September 20, 2023, by inventors Chen, Agrahari, Zhao, Nguyen, Zhang, Jiang, and O'Callaghan.
Ammonium Chloride Formulations for Viral Defense
The USPTO published patent application US20260097072A1 for ammonium chloride formulations designed to support human natural defense against viral infections. The invention claims compositions and methods using lysosomotropic agents, such as ammonium chloride (NH4Cl), to prevent viral uncoating within lysosomes of infected cells. The patent names Nikolaos Tsirikos-Karapanos and Nikolaos Drakoulis as inventors.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
735 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.